| Sara Kathleen Tallman, OTD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Sara Kathleen Tallman |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023555448 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 105282 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sara Kathleen Tallman, OTD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Sara Kathleen Tallman, OTD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
The Melanoma Research Alliance (MRA), the largest private funder of melanoma research, today announced grant awards exceeding $9.6 million to 49 scientists at leading academic institutions around the world for investigating new treatments and cures for melanoma.
"President Barack Obama on Wednesday renewed America's commitment to the recovery and reconstruction of earthquake-devastated Haiti, telling visiting President Rene Preval he knows the crisis has not passed," the Associated Press/TIME reports (Feller, 3/10).
UCLA bioengineers and colleagues at UNC School of Medicine and MIT have further developed a smart insulin-delivery patch that could one day monitor and manage glucose levels in people with diabetes and deliver the necessary insulin dosage.
Will Mr. Ryan be tempted to repeat a staple of his and Mr. Romney's stump speech, that the president has plundered $716 billion from Medicare to pay for "Obamacare?" There is danger there. Mr. Ryan incorporated the same $716 billion savings into his House budget this spring, and he has now renounced that plan because Mr. Romney promises to "restore" the money to Medicare.
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
› Verified 1 days ago
Amy L Krekelberg, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Danielle Anshus, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Erika Hope Mckeever, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Deborah Engen, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Susan D Hansen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mary B Clark, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |